Literature DB >> 2007290

The prognostic significance of urinary interleukin 6 in IgA nephropathy.

K Dohi1, M Iwano, A Muraguchi, Y Horii, T Hirayama, S Ogawa, H Shiiki, T Hirano, T Kishimoto, H Ishikawa.   

Abstract

Our previous study has shown that interleukin 6 (IL-6), a multifunctional cytokine, is closely associated with the pathogenesis of mesangial proliferative glomerulonephritis (mesPGN). To investigate whether urinary IL-6 can be used as an indicator in the prognosis of patients with IgA nephropathy, we monitored IL-6 activity in the urine of patients with IgA nephropathy for 10 months and compared IL-6 activity with clinical data as well as the histological changes of the kidneys obtained from the patients. It was found that among the patients who had continuously high urinary IL-6 activity, histological progression of IgA nephropathy was observed. On the other hand, among the patients whose urinary IL-6 became undetectable during the 10-month follow-up, histological improvement of IgA nephropathy was observed. These data suggest that the measurement of urinary IL-6 is a helpful tool for monitoring the progression of IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007290

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  15 in total

1.  Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy.

Authors:  L-L Liu; Y Jiang; L-N Wang; N Liu
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 2.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

3.  Altered production of IgE and IgA induced by IL-4 in peripheral blood mononuclear cells from patients with IgA nephropathy.

Authors:  N Yano; M Endoh; M Miyazaki; F Yamauchi; Y Nomoto; H Sakai
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 4.  FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.

Authors:  A W Thomson; P B Carroll; J McCauley; J Woo; K Abu-Elmagd; T E Starzl; D H Van Thiel
Journal:  Springer Semin Immunopathol       Date:  1993

Review 5.  n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis.

Authors:  James J Pestka
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-01       Impact factor: 4.006

Review 6.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

Review 7.  Expression of cytokines and growth factors in human glomerulonephritides.

Authors:  R Waldherr; I L Noronha; Z Niemir; C Krüger; H Stein; G Stumm
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

Review 8.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

Review 9.  The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system.

Authors:  H H Radeke; K Resch
Journal:  Clin Investig       Date:  1992-09

Review 10.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.